Phase II, randomised, multicentre study with two treatment arms (R-COMP versus R-CHOP) in newly diagnosed elderly patients (?60 years) with non-localised diffuse large B-cell lymphoma (DLBCL)/follicular lymphoma grade IIIb.
Read time: 1 mins
Last updated:10th Jun 2013
To assess reduced of subclinical cardiotoxicity, determined by differences in LVEF, which involves the incorporation of non-pegylated liposomal doxorubicin (Myocet�) when replacing conventional doxorubicin in the standard R-CHOP regimen (R-COMP) to treat newly diagnosed elderly patients with non-localised DLBCL/follicular lymohoma grade IIIb
|Study start date||2013-06-10|